New research suggests that cholesterol-lowering statins may play a
pivotal role in the development of new treatment for the progressive
neurological disorder Parkinson’s disease.
Parkinson’s is complex condition and different people may experience a
wide variety of different symptoms. Common symptoms however include:
tremors (shaking), rigidity (stiffness) and a slowness of physical
movements (known as bradykinesia).
Statins such as atorvastatin (Lipitor) and rosuvastatin (Crestor)
are currently taken by around 7 million people in Britain, and work by
decreasing rates of low-density lipoprotein (LDL) cholesterol (‘bad
cholesterol’) by reducing the production of LDL cholesterol inside the
liver. It is dangerous to have high rates of LDL cholesterol as this
causes the arteries to become narrower and harder (atherosclerosis),
causing a higher risk of heart attack, stroke and coronary heart
disease.
The history of statins can be traced back 42 years to 1971 when a
Japanese biochemist named Akira Endo, working at pharmaceutical company
Sankyo, pioneered the search for a drug that would help to
lower-cholesterol.
Since 1971, statins have soared in popularity and scientists have
unearthed other potential uses for the class of drugs, aside from their
cholesterol benefits – which last year were shown to have reduced heart attack deaths by half.
For instance, studies have linked statins to helping treat erectile dysfunction, liver cancer, and have even been explored as beneficial for asthma patients.
The new study into statins comes from Taiwanese research published online yesterday in the journal Neurology.
After analysis of almost 44,000 patients, scientists at the National
Taiwan University Hospital discovered that taking those patients who
stopped taking fat-soluble statins such as simvastatin (Zocor) or
atorvastatin (Lipitor) were approximately 58% more at risk of developing
Parkinson’s in comparison to patients who carried on taking the
statins.
Unlike water-soluble statins, it is generally believed that
fat-soluble statins pass through the blood-brain barrier, helping to
reduce inflammation and could even alter dopamine pathways in the brain
that are associated with Parkinson’s.
The Taiwanese national health insurance program has forbidden doctors
to prescribe statins to a patient once their target cholesterol level
has been reached.
This policy will be scrapped Aug. 1, but has made it possible for
this study to compare the potential difference in Parkinson’s risk in
patients who stopped taking statins against those still taking them.
“This policy allowed us to see whether there was any difference in
the risk of Parkinson’s in people who stopped taking statins compared to
the ones who kept taking them, ” said study author Dr Jou-Wei Lin, a
cardiologist at National Taiwan University Hospital. “We are more glad
than surprised to demonstrate the relationship. Our analysis is
observational…and further clinical trials targeting the association
between statin use and Parkinson’s disease are still needed.”
Dr Kieran Breen, from the charity Parkinson’s UK, however warned
people who suffer with Parkinson’s should never treat themselves with
statin medication unless they have been advised to do so by their own
GP.
No comments:
Post a Comment